LabReflex

LabReflex

Pulse: Who’s Counting the Labs?

18 min · Gestern
Episode Pulse: Who’s Counting the Labs? Cover

Beschreibung

This episode looks at new pressure points in lab medicine: payment reporting, LDT oversight, liquid biopsy expansion, supplier stability, and compliance risk. PAMA reporting: CMS is collecting private-payer data for the Clinical Laboratory Fee Schedule, but Laboratory Economics reports CMS may not know exactly which labs qualify as “applicable laboratories.” That raises questions about data quality, enforcement, and future Medicare lab rates. Enhancing CLIA Act of 2026: A new bill from Rep. Neal Dunn would keep LDT oversight centered in CLIA/CMS rather than FDA device regulation. It proposes a public LDT database, more transparency around validation and performance, third-party validity confirmation, centralized error reporting, and stronger CMS authority when LDT validity is questioned. Guardant360 Liquid CDx: Guardant received FDA approval for an expanded liquid biopsy panel. The story highlights the growing role of blood-based genomic profiling in oncology, along with challenges around interpretation, limitations, and reimbursement. Bio-Rad and Elliott: Elliott reportedly built a stake in Bio-Rad. For labs, this is a reminder that vendor strategy and financial pressure can affect reagents, QC materials, instruments, service, and validated workflows. Key Takeaway Labs are being asked to support payment policy, regulatory oversight, precision medicine, supply chains, and compliance systems. The big question: are the people designing these systems accounting for how labs actually work?

Kommentare

0

Sei die erste Person, die kommentiert

Melde dich jetzt an und werde Teil der LabReflex-Community!

Loslegen

2 Monate für 1 €

Dann 4,99 € / Monat · Jederzeit kündbar.

  • Podcasts nur bei Podimo
  • 20 Stunden Hörbücher / Monat
  • Alle kostenlosen Podcasts

Alle Folgen

28 Folgen

Episode Pulse: Who’s Counting the Labs? Cover

Pulse: Who’s Counting the Labs?

This episode looks at new pressure points in lab medicine: payment reporting, LDT oversight, liquid biopsy expansion, supplier stability, and compliance risk. PAMA reporting: CMS is collecting private-payer data for the Clinical Laboratory Fee Schedule, but Laboratory Economics reports CMS may not know exactly which labs qualify as “applicable laboratories.” That raises questions about data quality, enforcement, and future Medicare lab rates. Enhancing CLIA Act of 2026: A new bill from Rep. Neal Dunn would keep LDT oversight centered in CLIA/CMS rather than FDA device regulation. It proposes a public LDT database, more transparency around validation and performance, third-party validity confirmation, centralized error reporting, and stronger CMS authority when LDT validity is questioned. Guardant360 Liquid CDx: Guardant received FDA approval for an expanded liquid biopsy panel. The story highlights the growing role of blood-based genomic profiling in oncology, along with challenges around interpretation, limitations, and reimbursement. Bio-Rad and Elliott: Elliott reportedly built a stake in Bio-Rad. For labs, this is a reminder that vendor strategy and financial pressure can affect reagents, QC materials, instruments, service, and validated workflows. Key Takeaway Labs are being asked to support payment policy, regulatory oversight, precision medicine, supply chains, and compliance systems. The big question: are the people designing these systems accounting for how labs actually work?

Gestern18 min
Episode Pulse: Who Controls the Diagnostic Front Door? Cover

Pulse: Who Controls the Diagnostic Front Door?

This week on LabReflex Pulse, Dr. Chris Zahner and Dr. Aakash Bhatia dive into a series of stories that all point toward a bigger shift happening inside laboratory medicine: diagnostics are becoming infrastructure. From Nebraska rapidly validating an Andes virus PCR assay during a hantavirus scare… to Epic and Labcorp deepening diagnostic workflow integration… to AI pathology consolidation and real-time infectious disease surveillance dashboards — the organizations controlling diagnostic workflows may increasingly shape the future of healthcare itself. This week’s topics: Nebraska’s rapid Andes virus PCR response Following a hantavirus outbreak aboard the MV Hondius cruise ship, the Nebraska Public Health Laboratory rapidly validated an Andes virus PCR assay before exposed passengers arrived in the United States. The story raises major questions about rare-pathogen preparedness and rapid assay deployment in the post-COVID era. WIRED coverage: https://www.wired.com/story/race-to-develop-andes-hantavirus-test/ [https://www.wired.com/story/race-to-develop-andes-hantavirus-test/] CDC Health Alert: https://www.cdc.gov/han/php/notices/han00528.html [https://www.cdc.gov/han/php/notices/han00528.html] WHO outbreak notice: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON600 [https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON600] Epic + Labcorp integration: interoperability or market positioning? Labcorp announced expanded integration with Epic Aura, giving Epic users broader access to Labcorp’s testing menu and specialty diagnostics workflows. Chris and Aakash discuss whether EHR workflow design may increasingly influence diagnostic utilization — and whether hospital outreach laboratories should be paying closer attention. Labcorp announcement: https://ir.labcorp.com/news-releases/news-release-details/labcorp-and-epic-expand-collaboration-advance-diagnostic [https://ir.labcorp.com/news-releases/news-release-details/labcorp-and-epic-expand-collaboration-advance-diagnostic] ARUP launches infectious disease positivity dashboard ARUP introduced a national infectious disease positivity trends dashboard using deidentified laboratory data to help identify emerging patterns and seasonal shifts. The episode explores whether large reference laboratories are quietly becoming real-time public health surveillance networks. ARUP announcement: https://www.aruplab.com/news/05-13-2026/arup-launches-national-infectious-disease-test-positivity-trends [https://www.aruplab.com/news/05-13-2026/arup-launches-national-infectious-disease-test-positivity-trends] Roche acquires PathAI Roche announced plans to acquire digital pathology company PathAI in a major move signaling that AI pathology is transitioning from experimental technology to enterprise infrastructure. Roche announcement: https://www.roche.com/media/releases/med-cor-2026-05-07 [https://www.roche.com/media/releases/med-cor-2026-05-07] Reuters coverage: https://www.reuters.com/legal/litigation/switzerlands-roche-agrees-acquire-us-based-pathai-2026-05-07/ [https://www.reuters.com/legal/litigation/switzerlands-roche-agrees-acquire-us-based-pathai-2026-05-07/] Quick Hit: Cepheid Xpert GI Panel Cepheid received IVDR CE marking for its multiplex GI PCR panel, capable of detecting 11 gastrointestinal pathogens in approximately 75 minutes. The conversation touches on the continued expansion of rapid syndromic molecular testing and what it may mean for the future of microbiology workflows. FDA summary: https://www.accessdata.fda.gov/cdrh_docs/reviews/K251721.pdf [https://www.accessdata.fda.gov/cdrh_docs/reviews/K251721.pdf] Cepheid announcement: https://www.morningstar.com/news/pr-newswire/20260513la58308/cepheid-receives-ce-marking-under-ivdr-for-xpert-gi-panel [https://www.morningstar.com/news/pr-newswire/20260513la58308/cepheid-receives-ce-marking-under-ivdr-for-xpert-gi-panel] Subscribe to LabReflex! For more conversations at the intersection of laboratory medicine, diagnostics, pathology, and healthcare strategy, subscribe wherever you get your podcasts.

19. Mai 202636 min
Episode Deep Dive: Your Quality Plan Is Not Your Quality System Cover

Deep Dive: Your Quality Plan Is Not Your Quality System

Your Quality Plan Is Not Your Quality System In this LabReflex deep dive, we break down a simple but important inspection-readiness idea: A quality plan is what the lab says it does. A quality system is what actually happens when something goes wrong. Many labs prepare for inspection by trying to show that failures never happen. But real quality is not about pretending the lab is perfect. It is about having a consistent, repeatable system for detecting problems, documenting them, reviewing them, correcting them, verifying the fix, and improving over time. Key framework Detect → Document → Review → Correct → Verify → Improve A strong quality system makes follow-up obvious. It helps the lab answer: *  How did we know there was a problem?  *  Where was it documented?  *  Who reviewed it?  *  What changed?  *  Did the fix work?  *  What improved because of it?  Main example We use critical value notification delays as an example. A weak response is: “Staff were reminded.” A stronger response asks: *  Why were the calls delayed?  *  Was there a shift-specific pattern?  *  Were contact numbers correct?  *  Was the escalation process clear?  *  Did the lab audit afterward to prove improvement?  Big takeaway The strongest labs are not the ones that claim they never have problems. They are the ones that can show their quality system in action. The goal is not perfection. The goal is control, learning, and consistent improvement.

13. Mai 202627 min
Episode Pre-Inspection Prep: Why Most Labs Prepare the Wrong Way Cover

Pre-Inspection Prep: Why Most Labs Prepare the Wrong Way

Most labs do not prepare poorly because they do not care. They prepare poorly because they prepare for the wrong thing. Instead of stress-testing how the lab actually functions, they often review policies, clean things up, and make sure staff can answer a few familiar questions. The problem is that inspectors are usually not looking for memorization. They are trying to figure out whether the system is real. Does the work actually happen the way the lab says it happens? Do staff know what to do when something goes wrong? Can the lab prove it? In this episode, we focus on three deceptively simple inspection questions that reveal far more than factual knowledge: What do you do when QC fails? How do you know this instrument is working correctly? What do you do with an unexpected result? These are not trivia questions. They are system questions. They test error handling, escalation, judgment, consistency, and whether the lab’s workflow and documentation actually match what leadership believes is happening. We also lay out a practical framework for running a more useful mock inspection. Instead of asking staff to repeat policy language, we argue that labs should build scenario-based exercises around real-world stress points. The goal is to test whether staff can explain what they would do, show how they would do it, and trace their answer back to actual records, logs, documentation, and escalation pathways. That is where the real weaknesses usually show up. A major theme in the conversation is that most labs do not have a pure knowledge problem. They have an alignment problem. One person gives one answer, another gives a slightly different one, and the exception pathway is often much less solid than leaders assume. That is exactly the kind of thing inspectors notice quickly. A lab may look fine on the surface and still be vulnerable if its people, workflow, and documentation do not line up under pressure. In the episode, we walk through a five-part framework for better pre-inspection prep: testing scenarios instead of memory, making staff show and not just tell, tracing every answer back to evidence, stress-testing the highest-value inspection questions, and scoring alignment rather than just correctness. The underlying point is simple: if you want to know whether your lab is actually ready, you have to simulate the moments when trust in the system is challenged. In this episode, we discuss: *  Why most mock inspections are too soft to be useful  *  What inspectors are really testing when they question frontline staff  *  Why QC failure, instrument trust, and unexpected results are such revealing scenarios  *  How to move from fact-recall exercises to scenario-based system testing  *  Why demonstration and documentation matter as much as verbal answers  *  How to score inspection readiness in a more realistic way  *  Why consistency across staff may be the most important signal of all  Key takeaway: If a lab wants to truly prepare for inspection, it should stop treating readiness like a quiz and start treating it like a system check. The real test is not whether one person can give a polished answer. It is whether the lab can respond consistently, correctly, and visibly when something does not go according to plan.

4. Mai 202626 min